期刊
FRONTIERS IN BIOSCIENCE-LANDMARK
卷 16, 期 -, 页码 1488-1504出版社
FRONTIERS IN BIOSCIENCE INC
DOI: 10.2741/3800
关键词
Pluripotent stem cell; Embryonic stem cell; T lymphocyte; B lymphocyte; NK cell; Review
资金
- Fund for Scientific Research, Flanders (FWO Vlaanderen), Stichting tegen Kanker
- Stichting tegen Kanker
- Interuniversity Attraction Poles (IUAP)
- Belgian Science Policy
- Instituut voor de Aanmoediging van Innovatie door Wetenschap en Technologie in Vlaanderen (IWT)
Stem cell transplant recipients and acquired or inherited immune-deficiency patients could benefit from the infusion of B, T and/or NK cells. These lymphoid cells can be generated in vitro from bone marrow derived CD34(+)CD45(+) hematopoietic stem cells (HSC). The number of cells that can be obtained in this way is limited especially in the adult. An alternative source may therefore constitute human pluripotent stem cells (PSC) such as embryonic (hESC) or induced pluripotent stem cells (hiPSC). Here, we focus on present knowledge on the generation of lymphoid cells from hESC. The two main obstacles for the generation of clinically relevant immune cells are the failure to generate from hESC long-term repopulating HSC which could be kept in culture for prolonged time; and insufficient knowledge of the selection process which generates mature T cells from CD4 CD8 double positive (DP) precursors in vitro.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据